Patient P-01431

Synthetic patientNBL-101 · Day 117 · 25–34 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Stable

Discontinuation risk

66%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 GI symptom burden −12% vs expected — Dietary Support Protocol NP-02
Day 48 Tolerance state changed — Unstable → Improving
Day 49 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 50 GI-04 recommended — GI Support Protocol GI-04
Day 51 Patient accepted — Started GI-04 in the companion
Day 57 ME-01 recommended — Monitoring Escalation ME-01
Day 58 Patient accepted — Started ME-01 in the companion
Day 59 GI symptom burden −32% vs expected — GI Support Protocol GI-04
Day 61 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 65 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days

Toxicity+8
Nutritional resilience+4
GI instability+2
Inflammatory activity-2
Treatment adherence+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: symptom burden −12%
GI Support Protocol GI-04Day 50
Result: symptom burden −32%
Monitoring Escalation ME-01Day 57
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

67%

probability of meaningful tolerance improvement

284 similar trajectories
81% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

46.3/100

improving · -9.0 vs previous 14 d

Toxicity

Blood

50.1/100

improving · -2.7 vs previous 14 d

Sleep quality

Wearable

42.4/100

improving · +2.3 vs previous 14 d

Energy level

Daily log

3.5/10

improving · +0.3 vs previous 14 d

Stress level

Daily log

5.8/10

improving · -0.9 vs previous 14 d

Steps

Wearable

4,626

improving · +767 vs previous 14 d

Adherence

Companion

53.5 %

improving · +3.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 36 from the failing basin, 52 from restoration.

Would help

SC-12 Supportive Compound
76% improved among 51 similar · onset 6 d · confidence 68%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 68%

Would not help

Keep histamine low
GI +4.9 next day on high-intake days · n 18
Keep simple carbs low
GI +4.5 next day on high-intake days · n 17

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Histamine load
+4.9detractor · 95%
Simple carbohydrates
+4.5detractor · 95%
Insoluble fibre
+1.7no signal · 36%
Spicy / capsaicin
-1.1no signal · 24%
Alcohol
+1no signal · 21%
Dietary fat load
+0.8no signal · 24%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 45
- WearableHRV 30 ms, trending down
Drug metabolism and exposure ↑55
- DNADPYD *2A → slower clearance
- BloodToxicity index 50
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 46 and rising
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
DPYD *2A heterozygous
Slower drug clearance
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2 · butyrate capacity 46/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 31 ms
Sleep: 7.2 h
Steps: 4,870
Resting HR: 64 bpm

Daily log: GI score 46, nutritional resilience 46, adherence 54.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01377	23%	S11	AD-05	no change	42
P-01483	23%	S14	AD-05	no change	35
P-01679	23%	S12	AD-05	no change	39
P-01350	23%	S19	BR-03	no change	34
P-01708	32%	S07	CR-01	improved	59
P-01696	31%	S20	CR-01	improved	59
P-01835	31%	S17	CR-01	improved	56
P-01371	30%	S06	CR-01	improved	63
P-01442	30%	S13	CR-01	improved	61
P-01388	29%	S17	CR-01	improved	59
P-01877	27%	S01	CR-01	improved	67
P-01430	24%	S05	CR-01	improved	54